Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase ...

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Merck KGaA said pimicotinib, an orally administered inhibitor for tenosynovial giant cell tumor, delivered positive results in a late-phase study. The German life-sciences and electronics company ...

Speaking of which, we noticed some great changes in KSB SE KGaA's (ETR:KSB) returns on capital, so let's have a look. We've discovered 1 warning sign about KSB SE KGaA. View them for free.

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing foreign-exchange effects and uncertainty over tariffs.

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial ...